Literature DB >> 22528322

Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.

A Alexander1, A Rehders2, R Riediger1, M Schmitt3, M Anlauf4, W T Knoefel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22528322     DOI： 10.1007/s12029-012-9380-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  26 in total

1.  Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

Authors:  R Hitt; D Castellano; M Hidalgo; R García-Carbonero; M Peña; A Brandariz; J M Millán; J J Alvarez Vincent; H Cortés-Funes
Journal:  Ann Oncol       Date:  1998-12       Impact factor: 32.976

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Authors:  P A Philip; M M Zalupski; V K Vaitkevicius; P Arlauskas; R Chaplen; L K Heilbrun; V Adsay; D Weaver; A F Shields
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

4.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Authors:  Volker Heinemann; Detlef Quietzsch; Frank Gieseler; Michael Gonnermann; Herbert Schönekäs; Andreas Rost; Horst Neuhaus; Caroline Haag; Michael Clemens; Bernard Heinrich; Ursula Vehling-Kaiser; Martin Fuchs; Doris Fleckenstein; Wolfgang Gesierich; Dirk Uthgenannt; Hermann Einsele; Axel Holstege; Axel Hinke; Andreas Schalhorn; Ralf Wilkowski
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Authors:  Giuseppe Colucci; Francesco Giuliani; Vittorio Gebbia; Maria Biglietto; Piergiorgio Rabitti; Generoso Uomo; Silvio Cigolari; Antonio Testa; Evaristo Maiello; Massimo Lopez
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

6.  Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.

Authors:  Nikolas H Stoecklein; Andreas M Luebke; Andreas Erbersdobler; Wolfram T Knoefel; Winfried Schraut; Pablo E Verde; Franziska Stern; Peter Scheunemann; Matthias Peiper; Claus F Eisenberger; Jakob R Izbicki; Christoph A Klein; Stefan B Hosch
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 7.  Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

Authors:  Fernando Rivera; Sara López-Tarruella; Ma Eugenia Vega-Villegas; Matilde Salcedo
Journal:  Cancer Treat Rev       Date:  2009-01-07       Impact factor: 12.111

8.  Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.

Authors:  V Heinemann; R Labianca; A Hinke; C Louvet
Journal:  Ann Oncol       Date:  2007-07-28       Impact factor: 32.976

9.  Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.

Authors:  W R Waud; K S Gilbert; G B Grindey; J F Worzalla
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.

Authors:  Asma Sultana; Paula Ghaneh; David Cunningham; Naureen Starling; John P Neoptolemos; Catrin Tudur Smith
Journal:  BMC Cancer       Date:  2008-07-08       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.